Nav: Home

Netmedi launches a digital solution for immuno-oncology follow-up

May 25, 2016

Finnish health technology company Netmedi has developed an innovative digital platform, Kaiku® Health IO, for the follow-up of patients treated with immune checkpoint inhibitors. The solution is about to enter multi-center clinical validation phase and has already attracted significant interest among a number of leading oncology clinics. Kaiku® Health IO provides a solution for enhanced management of immune-related adverse events, supporting patients and the care team throughout treatment and follow-up. Netmedi will launch Kaiku® Health IO Early Access Program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 4th 2016.

Kaiku® Health IO monitors the patients' health status in real-time and collects structured information about the impact of immunotherapy. The solution enables the care team to treat patients more effectively according to their individual needs, and to react timely to any alarming signals during patients' treatment and recovery.

"Cancer immunotherapy has the potential to significantly extend the lives of many cancer patients, which underlines the importance of systematic patient follow-up", says Professor Paolo A. Ascierto, Director at National Tumor Institute Fondazione G. Pascale, Naples, Italy. "In addition, the adverse event profile of immunotherapy differs from conventional oncological treatments. These events can be better managed if they are detected and treated early on. Immunotherapy sets new requirements for patient follow-up". The institute headed by Professor Ascierto is one of the leading immunotherapy centers in the world and has extensive experience in treating patients with immune checkpoint inhibitors.

Kaiku® Health IO has been developed in co-operation with several Finnish and European oncology experts. "Netmedi is committed to supporting the treatment of cancer patients by developing easy-to-use, intelligent digital services for patient-centric follow-up", says the CEO of Netmedi Lauri Sippola.
-end-


Netmedi

Related Immunotherapy Articles:

Barrier Proteins in Tumors are Possible Key to Immunotherapy Success
By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute and the Memorial Sloan-Kettering Cancer Center say their findings have the potential to reveal some of the mechanisms underlying response or resistance to immunotherapy drugs.
Discovery could guide immunotherapy for lung cancer
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment, according to a Cancer Research UK funded study* published today (Monday) in Nature Immunotherapy.
Genetic mutations predict patient response to immunotherapy
Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade.
'Immunoswitch' particles may be key to more-effective cancer immunotherapy
Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice.
Early research suggests first immunotherapy for mesothelioma on the horizon
Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising.
A new T-cell population for cancer immunotherapy
Scientists at the University of Basel in Switzerland have, for the first time, described a new T cell population that can recognize and kill tumor cells.
Immunotherapy target suppresses pain to mask cancer
Duke University researchers found that a molecule called PD-L1, which is blocked by the immunotherapy drug nivolumab, acts not only on immune cells but also on the nerve cells that signal pain.
Immunotherapy against bee stings in some cases incomplete
The preparations that are used for allergen immunotherapy against bee sting allergies do not always contain all the relevant venom components.
New imaging method may predict immunotherapy response early
A noninvasive PET imaging method that measures granzyme B, a protein released by immune cells to kill cancer cells, was able to distinguish mouse and human tumors that responded to immune checkpoint inhibitors from those that did not respond early in the course of treatment.
T cell revival correlates with lung cancer response to PD-1 immunotherapy
In lung cancer patients who were taking immunotherapy drugs targeting the PD-1 pathway, testing for CD8 T cell activation in their blood partially predicted whether their tumors would shrink.

Related Immunotherapy Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...